This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IntegraMed America's CEO Discusses Q3 2011 Results - Earnings Call Transcript

IntegraMed America, Inc. ( INMD)

Q3 2011 Earnings Call

November 3, 2011 10:00 am ET

Executives

Jay Higham – President & Chief Executive Officer

Tim Sheehan – Senior Vice President & Chief Financial Officer

Analysts

Kevin Ellich – Piper Jaffray

Brooks O’Neil – Dougherty & Co.

Nick Halen – Sidoti & Company

Presentation

Operator

Good morning. My name is Joanne and I will be your conference Operator today. At this time I would like to welcome everyone to the IntegraMed Q3 Earnings Conference Call. (Operator instructions.) Thank you. Mr. Sheehan, you may begin your conference.

Tim Sheehan

Good morning, everyone, and thank you for participating in IntegraMed’s Q3 conference call. This is Tim Sheehan, Senior Vice President, CFO. I am joined today by Jay Higham, President and CEO.

Before we begin I would like to caution that some of the comments made on this call may refer to certain measures such as normalized earnings, which are not calculated in accordance with generally accepted accounting principles or GAAP. Management believes these results are representative of the performance of the ongoing business of the company. Please see the company’s press release furnished as an exhibit to its current report on Form 8(k) filed with the Securities and Exchange Commission, and which may be found under the News tab of the company’s website.

The content of this conference call contains time sensitive information that is accurate only as of today, November 3, 2011. IntegraMed undertakes no obligation to revise or update any statements to reflect events or circumstances occurring after the date of this conference call.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs